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ABSTRACT 
 
Aims: To investigate the adaptations of left ventricular function and calcium handling to 
chronic heart rate reduction with ivabradine in the reperfused heart. 
Methods and Results: Rabbits underwent 20-min coronary artery occlusion followed by 3 
weeks of reperfusion. Throughout reperfusion, rabbits received ivabradine (10 mg/kg/day) or 
vehicle (Control). Ivabradine reduced heart rate by about 20% and improved both ejection 
fraction (+35%) and systolic displacement (+26%) after 3 weeks of treatment. Interestingly, 
this was associated with a 2-fold increase expression of FKBP12/12.6. There was no 
difference in the expressions of phospholamban, SERCA2a, calsequestrin, ryanodine, 
phospho-ryanodine and Na2+/Ca2+ exchanger in the two groups. Infarct scar and vascular 
density were similar in both groups. Administration of a single intravenous bolus of 
ivabradine (1 mg/kg) in control rabbits at 3 weeks of reperfusion also significantly improved 
acutely ejection fraction and systolic displacement. 
Conclusion: Chronic heart rate reduction protects the myocardium against ventricular 
dysfunction induced by myocardial ischaemia followed by 3 weeks of reperfusion. Beyond 
pure heart rate reduction, ivabradine improves global and regional systolic function of the 
reperfused heart through a dual mechanism involving a direct mechanical effect and a long-
term adaptation in calcium handling, as supported by the increase in FKBP12/12.6 expression. 
 
KEYWORDS: Left ventricular dysfunction; infarction; calcium handling; chronic heart rate 
reduction; If- channel; ivabradine. 
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INTRODUCTION 
Inhibition of the cardiac pacemaker If current by ivabradine induces pure heart rate 
reduction, exerts anti-ischaemic properties and protects against myocardial stunning and 
infarction 1-5. Several experimental studies have also demonstrated that chronic treatment with 
ivabradine improves global left ventricular (LV) function and reduces cardiac collagen 
accumulation in rats with congestive heart failure induced by permanent coronary artery 
ligation 6, 7 , 8, 9. One possible mechanism is a direct Frank-Starling mechanical effect 
secondary to an increase in end-diastolic volume with heart rate reduction, as suggested by 
previous results observed during myocardial stunning 3, 10. An improvement in both calcium 
transient amplitude and SERCA function could also explain the beneficial effects of 
ivabradine on left ventricular dysfunction after permanent coronary artery ligation 11. 
However, the mechanism for this improvement in left ventricular function remains to be 
determined. Indeed, there is a paucity of results concerning the effects of chronic pure heart 
rate reduction on calcium handling and especially FKBP12/12.6 expression. This is of 
importance as FKBP12/12.6 modulates cardiac excitation-contraction coupling through its 
binding to the ryanodine receptor RyR2 12, 13 and mediates coupled gating observed in RyR2 
channel clusters 14. This prevents calcium leak from the sarcoplasmic reticulum, thereby 
ultimately increasing contractility 12, 13. Finally, it is important to emphasize that these long-
term beneficial effects of ivabradine on post-infarction LV dysfunction have been investigated 
only in models of permanent coronary ligation, i.e., in the absence of coronary artery 
reperfusion 6-9, 11. Such models do not properly reflect the clinical situation as to date, most of 
patients with acute myocardial infarction undergo coronary revascularization with 
angioplasty, thrombolysis surgery or spontaneous recanalization, i.e., they are exposed to LV 
dysfunction and remodelling resulting from both a loss of contractile tissue and altered 
salvaged territory. 
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The aim of the present study was thus to investigate for the first time the effects of chronic 
heart rate reduction in rabbits undergoing coronary artery occlusion followed by 3 weeks of 
reperfusion, i.e., a clinically relevant experimental model of post-infarction. We evaluated 
global and regional LV systolic functions and remodelling in the post-infarction period in the 
presence or absence of continuous administration of ivabradine. Changes in the proteins 
involved in calcium handling, including the ryanodine channel (RyR2), SERCA2a, Na+/Ca2+ 
exchanger (NCX1), calsequestrin as well as modulatory proteins, such as FKBP12/12.6 and 
phospholamban, were also investigated. Among these, FKBP12/12.6 is of particular 
importance as its deficiency participates in heart failure 15 whereas its overexpression 
increases calcium transient amplitude and cell shortening 13, 16. 
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METHODS 
The animal instrumentation and the ensuing experiments were conducted in accordance 
with French official regulations. All experiments were performed in male New Zealand 
rabbits (3.0-3.5 kg). 
Protocol 
As illustrated in figure 1, rabbits were randomly divided into Control and Ivabradine 
groups receiving saline and ivabradine (10 mg/kg/day during 21 days), respectively. 
Rabbits were anesthetized using zolazepam and tiletamine (20-30 mg/kg each, IV) and 
then intubated and mechanically ventilated. Anesthesia was maintained by pentobarbital (20-
30 mg/kg iv). An external electrocardiogram was recorded. A left thoracotomy was performed 
under sterile conditions and the pericardium was opened. A 3/0 polypropylene suture was 
passed beneath a major branch of the left coronary artery. The ends of the ligature were 
passed through a short segment of propylene tubing to form a snare and coronary artery 
occlusion (CAO) was induced by pulling the snare through the tubing for 20 min. Reperfusion 
was subsequently induced by releasing the snare and the chest was then closed in layers. 
Osmotic pumps (Alzet 2ML4, Durect, Cupertino, CA, USA) were then subcutaneously 
implanted in order to deliver either saline or ivabradine. Antibiotic (spiramycin, 30 mg/kg/day 
IM) and analgesics (flunixin meglumine, 1 mg/kg/12h IM; buprenorphine, 0.02 mg/kg/12h 
SC) were given for 5 and 2 consecutive days following surgery, respectively. Rabbits were 
submitted to regular echocardiographic evaluations at baseline (1 week before surgery) as 
well as at days 3, 7, 14 and 21 of reperfusion. 
In order to distinguish between the effects of acute heart rate reduction as opposed to those 
observed during chronic ivabradine administration, all rabbits in the control group received 
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ivabradine at day 21 as a single bolus (1 mg/kg IV). Echocardiographic recordings were 
performed before and 30 min after this acute administration of ivabradine. 
Echocardiography 
During each echocardiographic evaluation, rabbits were sedated with diazepam (2-4 mg/kg 
IP) and a standard transthoracic echocardiography was performed using an ultrasonographic 
unit instrumented with a 6-12 MHz phased-array transducer Vivid 7 (General Electric 
Medical System, Waukesha, WI, USA). Ventricular measurements were obtained in the right 
parasternal location (short-axis view) using a 2D–guided M-mode. Systolic and diastolic LV 
areas were evaluated and LV volume was estimated using the Simpson approximation. 
Ejection fraction was calculated and expressed as a percentage. End-systole and end-diastole 
were determined using ECG as the end of the T wave and the onset of the QRS, respectively. 
Using the same ultrasonographic unit, 2D colour tissue Doppler imaging was performed in 
radial motion with right parasternal ventricular short-axis views. Receiving gain of the grey 
scale was set to optimize clarity of the endocardial and epicardial boundaries of the left 
ventricular free wall during each examination. Real-time colour Doppler images were 
superimposed on the grey scale at frame rate ≥ 200 frames/s. Doppler receiving gain was 
adjusted to maintain optimal colour of the myocardium. The systolic displacement of the LV 
free wall was calculated using tissue tracking imaging, i.e., by integration of the velocity 
signal according to the time. It should be acknowledged that our preliminary experiments 
demonstrated that the signal-to-noise ratio of strain and strain rate imaging was poor and it did 
not allow accurate assessment of the regional function compared with tissue tracking. 
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Measurement of risk area and infarct size 
The hearts were collected after 3 weeks of reperfusion. The ascending aorta was 
cannulated and perfused retrogradely with Alcyan blue (1%) after ligation of the previously 
occluded artery. The left ventricle was cut into 6 to 8 slices which were weighed and 
incubated with 1% triphenyltetrazolium chloride (TTC, Sigma, Poole, U.K.) in a pH 7.4 
buffer at 37°C. Slices were fixed in 10% formaldehyde and then photographed with a digital 
camera mounted on a stereomicroscope. The area at risk and the infarcted zones were 
quantified using a computerized planimetric program (Image J-1.37, National Institute of 
Health, Bethesda, ML, USA). The area at risk was identified as the non-blue region and was 
expressed as a percentage of the LV weight. Infarcted area was identified as the TTC-negative 
tissue and was expressed as a percentage of the area at risk. 
Histology and immunohistochemistry 
Slices from the middle part of the heart were fixed in formalin and embedded in paraffin 
for histology and immunohistochemistry. Histological abnormalities were investigated using 
hematoxylin-eosin-saffron (HES) as previously described 17, 18. The size of infarct scar was 
also assessed on scanned HES sections using a scanner (Tribvn, Chatillon, France) and Image 
J program. Anti-CD31 monoclonal antibody (Dako, Trappes, France) was used as an 
endothelial cell marker in order to identify microcirculatory network. Capillary density was 
evaluated in the border zone surrounding infarct scar as well as in the myocardium that did 
not undergo the initial coronary artery occlusion. In each territory, 10 fields were analyzed at 
X20 magnification: the number of CD-31 labeled capillary sections was counted in each field. 
Sirius red staining was also performed and used to quantify the interstitial fibrosis that was 
quantified in the border zone surrounding infarct scar and expressed as a percentage of the 
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field area (10 fields analyzed at X20 magnification): the interstitial fibrosis was measured 
with image analysis using NIS Elements program (Nikon, Champigny, France). 
Western Blots 
A second set of rabbits, i.e., 5 control and 4 ivabradine rabbits underwent 20-min coronary 
artery occlusion followed by 21 days of reperfusion in order to investigate calcium handling. 
Finally, a third set of animals was investigated, i.e., 4 SHAM-operated and 4 other control 
rabbits. Myocardial samples were homogenized in ice-cold buffer containing 50mM Tris-HCl 
(pH 7.4 at 4°C), 150mM NaCl, 1mM EDTA, 5µL/mL protease inhibitor cocktail, 1 mM 
sodium orthovanadate, 5 mM sodium fluoride and 1 mM sodium Na2β-glycerol phosphate (all 
from Sigma, L’Isle d’Abeau Chesnes, France) and centrifuged (40,000g for 30 min at 4°C). 
The protein concentration was determined using a BCA Protein Assay Kit (Pierce, Rockford, 
IL, USA). Proteins were separated on SDS-polyacrylamide gels and transferred to PVDF 
membrane (Millipore, Bedford, MA, USA). After blocking with 5% nonfat dry milk in Tris-
buffered saline containing 0.1% Tween-20 (TBS-T), membranes were incubated for 1h at 
room temperature with primary antibodies against cardiac ryanodine receptor (RyR2), FKBP 
12/12.6, calsequestrin, SERCA 2a, phospholamban (all from Affinity Bioreagents, Golden, 
CO, USA), phosphorylated cardiac ryanodine receptor (P-RyR2) (Badrilla, Leeds, UK) or 
Na2+/Ca2+ exchanger (NCX1) (1/1000, Abcam, Cambridge, UK). The membranes were then 
washed three times with TBS-T for 10 min and subsequently incubated for 1h with the 
appropriate secondary antibody conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology, CA, USA). Bands were visualized with chemiluminescence (ECL Western 
Blotting Substrate, Pierce, IL, USA), scanned and quantified in a blinded manner using gel 
analysis software (Image J-1.37, National Institute of Health, Bethesda, MD, USA). 
Calsequestrin was used as standard for controlling equal loading. 
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Statistical Analysis  
All data were expressed as mean ± SEM. Statistical analysis was performed using animals 
that successfully underwent the whole protocol. Heart rate and echocardiographic parameters 
were compared at baseline using an unpaired Student t test. Data collected during reperfusion 
(day 3 to day 21) were analysed using two-way ANOVA for repeated measures (repeated 
times nested in treatments) with treatment effect, time effect and time*treatment interaction. 
Individual comparisons were performed using an unpaired Student t test. Values at day 21 in 
the control group were also compared before and after the IV bolus of ivabradine using a 
paired Student t test. Western blot results were analysed using a Mann-Whitney test. 
Differences were considered significant for P≤0.05 and the tests were two-sided. Statistical 
analyses were performed using Statview 5.0 (Abacus Concepts, Berkeley, CA, USA). 
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RESULTS 
Out of the 26 rabbits that underwent to the initial surgery, 22 survived coronary artery 
occlusion and the first hours of reperfusion. Another 5 rabbits (4 Control and 1 Ivabradine) 
died at days 2, 7, 14, 15 and 20 following surgery. There were therefore 9 and 8 rabbits in the 
control and ivabradine groups, respectively. 
Heart rate  
Heart rate was similar between Control and Ivabradine at baseline but was significantly 
decreased throughout reperfusion in Ivabradine as compared to Control (-20%, -12%, -18% 
and -20%, at days 3, 7, 14 and 21, respectively) (Table 1). 
In Control, bolus administration of ivabradine at day 21 also induced a significant decrease 
in heart rate (-24±2%). 
Left ventricular function 
As shown in Table 1, the reperfusion period was associated with a LV dilatation as shown 
by the progressive increases in LV diastolic volumes in Control. Heart rate reduction with 
ivabradine induced significant increases in LV diastolic volumes and also improved LV 
systolic volumes. As a result (Figure 2), ejection fraction was preserved in Ivabradine with 
significantly greater values as compared to Control (e.g., a 35% increase at day 21). Similarly, 
regional function assessed by systolic displacement was increased in ivabradine as compared 
to Control (e.g., by 26% at Day 21) (Figure 2). 
As shown in Figure 3, single bolus administration of ivabradine in Control at day 21 also 
induced a significant increase in ejection fraction (+26±7%) along with an improved systolic 
displacement. 
  
11 
Western Blots 
There was no significant difference in calsequestrin, NCX1, RyR2, P-RyR2, SERCA2a 
and phospholamban between Ivabradine (n=4) and Control (n=5) (Figure 4). Interestingly as 
illustrated in Figure 5, FKBP12/12.6 was increased by 96% in Ivabradine as compared to 
Control. 
In the third set of investigated animals, the comparison between SHAM (n=4) and Control 
(n=4) revealed significant decreases in RyR2 (1.1±0.1 vs 0.4±0.1, respectively) and 
SERCA2a (0.8±0.1 vs 0.5±0.1) and increase in NCX1 (1.4±0.1 vs 1.6±0.1). Calsequestrin, 
phospholamban and FKBP12/12.6 remained similar between the 2 groups (15760±555 vs 
17058±1321 Arbitrary Units, 1.2±0.2 vs 1.0±0.1 and 1.0±0.1 vs 0.9±0.1, respectively). 
Macroscopic pathology and histology 
Analyses were performed in all animals that completed the whole protocol (9 Control and 
8 ivabradine). LV weights, area at risks and infarct sizes were similar in Control and 
Ivabradine (6.6±0.4 vs 6.7±0.4g, 29±2 vs 29±3% and 25±3 vs 28±5%, respectively). 
Histology also revealed similar infarct scar sizes in Control and Ivabradine. 
Concerning fibrosis (Figure 6), Sirius red staining of histological left ventricular slices did 
not reveal interstitial fibrosis in the remote non ischaemic zone in either group. However, a 
huge interstitial fibrosis was observed in the peri-infarction border zone with a similar extent 
in both groups (12.9±2.3 and 9.5±2.6% of the microscopic fields' area in Ivabradine and 
Control). 
Microvascular labelling using CD31 immunohistochemistry revealed a dramatic decrease 
in the microvessel density in the peri-infarction zone vs remote non ischaemic myocardium in 
both groups. Microvessel densities were similar in the two groups. They averaged 366±33 and 
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302±30 vessels/µm2 in the peri-infarction territory vs 1021±36 and 944±41 vessels/mm2 in the 
remote non ischaemic territory in Control and Ivabradine, respectively. 
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DISCUSSION 
The present study provides new informations on the beneficial effects of chronic pure heart 
rate reduction in the post-infarcted and reperfused myocardium. Our results show that 
ivabradine-induced heart rate reduction protects against LV dysfunction following myocardial 
infarction and reperfusion through two potential mechanisms: 1) a pure mechanical effect as 
demonstrated by the functional consequences of acute administration of ivabradine in the 
control group and 2) a chronic adaptation of calcium handling in the myocardium as 
supported by an increase in FKBP12/12.6 expression, which is known to be deficient in 
failing hearts 15. 
The functional results obtained in this study cannot be superimposed on those of previous 
investigations of ivabradine in a post-infarction situation 6-9, 11. Indeed, these reports involve 
experimental models of permanent coronary artery ligation which induces profound 
ventricular remodelling associated with the development of congestive heart failure. In the 
context of LV dysfunction that occurs after myocardial infarction, we believe that our 
experimental setting is more clinically relevant because the ischaemic area was reperfused. In 
our rabbit model of ischaemia-reperfusion, systolic dysfunction and ventricular dilation were 
related to an infarct scar size averaging 7% of the left ventricle, i.e., dramatically smaller than 
that observed in models of permanent coronary artery ligation (~40% of the left ventricle in 
rats) 6, 7. We did not observe any histological evidence of myocardial remodelling in the 
remote territory not submitted to ischaemia, which means that our model can not be 
considered as a classical global deleterious remodelling and that our results cannot be 
superimposed on previous results obtained using ivabradine in congestive heart failure 
following permanent coronary artery ligation 6, 7. Finally our model leads to a mixed region 
  
14 
containing both infarcted and salvaged tissues. Importantly, it also allows investigation of the 
regional function of the reperfused area. 
The observed LV dysfunction could result from myocardial stunning of the salvaged areas 
with reperfusion, the loss of contractile tissue resulting from infarction and ventricular 
remodeling. We did not specifically investigate this issue but several aspects could be 
discussed. Firstly, infarction affected only a small part of the left ventricle (7%) and therefore 
the direct loss of contractile tissue secondary to necrosis did not induce per se a dramatic 
decrease in ejection fraction. Secondly, the contribution of LV remodeling could be suggested 
from the progressive deterioration in ejection fraction of control rabbits that was prevented by 
chronic administration of ivabradine. Finally, the analysis of systolic displacement within the 
area at risk clearly revealed myocardial stunning as a progressive return to baseline occurred 
in control animals. In agreement with our previous results 3, it is reasonable to conclude that 
ivabradine reduced myocardial stunning in the present study. 
In the present study, chronic administration of ivabradine significantly decreased heart rate 
by an average of 18 %, i.e., similar to that reported in previous studies performed in rats 7, 
dogs 3, 19 and pigs 4. This effect was constant over the 3 weeks of reperfusion. In these 
conditions, heart rate reduction preserved ejection fraction as opposed to its progressive 
alteration observed in Control. These beneficial effects were not related to differences in 
infarct sizes as a similar amount of myocardial damage was observed in the two groups. This 
is in apparent contradiction with a previous investigation 4 demonstrating a significant 
reduction in infarct size with ivabradine. However it must be emphasized that those authors 
administered ivabradine before ischaemia whereas its administration was started only after 
reperfusion in the present study, thus avoiding the infarct-limiting effect of ivabradine 4. 
Furthermore, no significant difference in the size of the area at risk was observed between the 
two groups of rabbits. It should also be stressed that the improvement in LV function cannot 
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be the consequence of a reduction in fibrosis or an increase in capillary density with 
ivabradine, as opposed to previous results described in models of heart failure with permanent 
coronary artery ligation 7, 9. This apparent discrepancy is most likely the consequence of 
differences in experimental models, i.e., a reperfused vs a ligated territory. A longer period of 
follow-up over several months as opposed to the 3 weeks of reperfusion in our study might be 
necessary to reveal such differences. 
The beneficial effects of ivabradine on post-infarction systolic function can be explained 
by two mechanisms. The single bolus administration performed at day 21 of reperfusion in 
control animals induced a significant increase in systolic displacement and ejection fraction. 
This suggests that heart rate reduction also improves global and regional systolic function 
through a direct and acute mechanical effect. This observation is in accordance with previous 
reports demonstrating that acute heart rate reduction with ivabradine improves systolic wall 
thickening and reduces post-systolic motion in the stunned myocardium 3, 10. Improved left 
ventricular filling, a Frank-Starling mechanism associated with a greater diastolic coronary 
perfusion, is certainly involved in this direct effect. 
The second and novel mechanism is related to a chronic change in calcium handling. In our 
experimental conditions, expressions of SERCA2a and RyR2 were significantly reduced in 
control as compared to SHAM rabbits and that of NCX1 was increased, without any change 
in FKBP12/12.6, calsequestrin or phospholamban. Administration of ivabradine did not 
change the expression of NCX1, RyR2 and its phosphorylated form, SERCA2a, 
phospholamban or calsequestrin as compared to Control at 3 weeks of reperfusion. However, 
the important observation is that the expression of FKBP12/12.6 was doubled by chronic 
administration of ivabradine. Such increase was not only a return to baseline values but rather 
a significant increase in expression which went beyond normal levels. Although it was not 
directly demonstrated, it is reasonable to speculate that the increase in FKBP12/12.6 
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expression observed in the present study participates to the improvement in global and 
regional cardiac function induced by chronic administration of ivabradine. Indeed in the heart, 
FKBP12/12.6 modulates cardiac excitation-contraction coupling through its binding to RyR2 
12, 13
. It mediates coupled gating of RyR2 channel clusters 14 and prevents calcium leak from 
the sarcoplasmic reticulum, thereby ultimately increasing contractility 12, 13. Interestingly, 
FKBP12/12.6 deficiency has been shown to participate in heart failure 15 and arrhythmias 20. 
Conversely, overexpression of FKBP12 in rabbit cardiomyocytes using adenoviral-mediated 
gene transfer increases systolic calcium transient amplitude secondary to a higher degree of 
excitation-contraction coupling synchrony 12. A similar increase in FKBP12/12.6 expression 
has also been previously demonstrated with late preconditioning against myocardial stunning 
21
. Interestingly and in particular relevance to our results, its overexpression increases calcium 
transient amplitude and cell shortening 13, 16, and can improve cardiac function in post-
myocardial infarction in rats 22. To our knowledge, the present study is the first to describe an 
increase in FKBP12/12.6 with chronic heart rate reduction. This observation is particularly 
interesting in the context of the development of pharmacological agents that stabilize the 
RyR2-FKBP12/12.6 interaction and that are known to improve myocardial function, to inhibit 
calcium leak from the sarcoplasmic reticulum and to prevent arrhythmias 20, 23. 
Regarding the effects of ivabradine in the present study, one can conclude that part of its 
protective effects are directly related to heart rate reduction per se, as suggested by the 
improvement in LV function observed after the single bolus administration of ivabradine in 
the control group at 21 days of reperfusion. Similar acute changes have been previously 
reported in the stunned myocardium 3. However, as we did not perform experimental studies 
in which heart rate was corrected with pacing, one cannot rule out the possibility of 
pleiotropic properties of ivabradine beyond pure heart rate reduction 24. Indeed, a previous 
report has demonstrated in an established pig model of regional myocardial ischemia-
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reperfusion that the protective effects of ivabradine on myocardial infarction were only 
partially reversed by atrial pacing 4. Interestingly during heart failure, If expression is 
increased in the ventricular myocytes during heart failure 25. Such channel can also contribute 
to calcium currents 26 and possibly to calcium overload. Therefore part of the observed 
beneficial effects of ivabradine could be exerted directly on the left ventricular myocardium. 
These results may have general implications regarding heart rate reduction after 
myocardial infarction. It is reasonable to speculate that the effects observed in the present 
study could be generalized to other bradycardic agents, i.e., mostly β-blockers. However, it 
should be noted that the potential pleiotropic effects would be restricted to If channel blockers 
such as ivabradine or UL-FS 49 27. However additional negative inotropic properties of β-
blockers might alter the consequences of heart rate reduction. As previously demonstrated 
during acute stunning, the negative inotropic of β-blockers effect might have deleterious 
effects on LV function 3. In addition, β-blockers slow the rate of isovolumic relaxation and 
therefore, impede coronary blood flow whereas this effect is not observed with ivabradine 28, 
29
. Importantly, β-blockade unmasks α-adrenergic mediated coronary vasocontriction 29. In 
contrast, ivabradine has no direct effect on coronary vasomotion: it does not unmask α-
adrenergic coronary vasoconstriction and also preserves endothelium-mediated vasodilation 
that is typically observed in large coronary arteries in response to increased shear stress 1. 
In conclusion, chronic heart rate reduction with ivabradine protects the myocardium 
against ventricular dysfunction in a clinically relevant model of myocardial infarction 
followed by reperfusion. Beyond pure heart rate reduction, chronic administration of 
ivabradine improves global and regional systolic function of the reperfused heart through a 
dual mechanism involving a direct mechanical effect and a long-term adaptation in calcium 
handling, as supported by an increase in FKBP12/12.6 expression. As FKBP12/12.6 
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deficiency has been reported as one possible trigger of LV dysfunction and heart failure, the 
present study opens new insights regarding the long-term benefits of chronic heart rate 
reduction with ivabradine. 
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LEGENDS OF FIGURE 
Figure 1 
Experimental protocol (CAO, coronary artery occlusion). 
Figure 2 
Evolution of ejection fraction and systolic displacement measured at baseline and during the 3 
weeks of reperfusion in Control and Ivabradine (CAO, coronary artery occlusion). *, P<0.05 
vs Control. 
Figure 3 
Ejection fraction and systolic displacement measured before and after a single administration 
of ivabradine (1 mg/kg, IV bolus) in Control at day 21. Open circles represent individual data 
and closed circles are mean ± SEM. *, P<0.05 vs "Before". 
Figure 4 
Western blots of calsequestrin, Na2+/Ca2+ exchanger (NCX1), ryanodine (RyR2), 
phosphorylated ryanodine (P-RyR2), SERCA2a, and phospholamban obtained after 3 weeks 
of reperfusion in Control and Ivabradine. 
Figure 5 
Western blot of FKBP12/12.6 obtained after 3 weeks of reperfusion in Control and 
Ivabradine. *, P<0.05 vs Control. 
Figure 6 
Sirius red staining (Panel A, bar=100µm) and immunohistochemical labelling of the 
endothelial marker CD31 (Panel B, bar=200µm) of the left ventricle in the remote and peri-
infarction territories in Control and Ivabradine. 
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Table I: Hemodynamic parameters
Day 3 Day 7 Day 14 Day 21 Group 
effect
Time 
effect
Group x 
time
Control 263±11 292±10 261±10 264±8 266±14
Ivabradine 255±8 234±10 229±13 216±9 214±9
Left ventricular diastolic volume (ml/kg )
Control 0.74±0.07 0.92±0.07 1.10±0.14 1.13±0.10 1.37±0.11
Ivabradine 0.82±0.06 1.16±0.06 1.17±0.06 1.29±0.07 1.42±0.10
Left ventricular systolic volume (ml/kg )
Control 0.27±0.02 0.42±0.03 0.59±0.09 0.63±0.08 0.79±0.10
Ivabradine 0.27±0.02 0.46±0.05 0.45±0.04 0.52±0.03 0.59±0.05
Values are mean ± SEM.
Heart rate
P=0.0022 P=0.2768
P<0.0001 P=0.0742 P=0.5930
P=0.0276
Reperfusion
Baseline
P value (Reperfusion period)
P=0.7138P=0.0019P=0.0452
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Figure 2 
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Figure 5 
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Figure 6 
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